text_1: 患者 纳入 标准 是 新 诊断 出 晚期 高级别 卵巢癌 , 并且 对 一线 铂 类 - 紫杉 类药物 化疗 + 贝伐珠 单抗 治疗 产生 应答 .
  
text_2: eligible patients had newly diagnosed , advanced , high @-@ grade ovarian cancer and were having a response after first @-@ line platinum @-@ taxane chemotherapy plus bevacizumab .
  